Show simple item record

dc.contributor.authorJeon, WJ
dc.contributor.authorDean, B
dc.contributor.authorScarr, E
dc.contributor.authorGibbons, A
dc.date.accessioned2020-12-22T04:19:12Z
dc.date.available2020-12-22T04:19:12Z
dc.date.issued2015-01-01
dc.identifierpii: CN-EPUB-68055
dc.identifier.citationJeon, W. J., Dean, B., Scarr, E. & Gibbons, A. (2015). The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?. CURRENT NEUROPHARMACOLOGY, 13 (6), pp.739-749. https://doi.org/10.2174/1570159X13666150612230045.
dc.identifier.issn1570-159X
dc.identifier.urihttp://hdl.handle.net/11343/258042
dc.description.abstractThe central cholinergic system has been implicated in the pathophysiology of mood disorders. An imbalance in central cholinergic neurotransmitter activity has been proposed to contribute to the manic and depressive episodes typical of these disorders. Neuropharmacological studies into the effects of cholinergic agonists and antagonists on mood state have provided considerable support for this hypothesis. Furthermore, recent clinical studies have shown that the pan-CHRM antagonist, scopolamine, produces rapid-acting antidepressant effects in individuals with either major depressive disorder (MDD) or bipolar disorder (BPD), such as bipolar depression, contrasting the delayed therapeutic response of conventional mood stabilisers and antidepressants. This review presents recent data from neuroimaging, post-mortem and genetic studies supporting the involvement of muscarinic cholinergic receptors (CHRMs), particularly CHRM2, in the pathophysiology of MDD and BPD. Thus, novel drugs that selectively target CHRMs with negligible effects in the peripheral nervous system might produce more rapid and robust clinical improvement in patients with BPD and MDD.
dc.languageEnglish
dc.publisherBENTHAM SCIENCE PUBL LTD
dc.titleThe Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?
dc.typeJournal Article
dc.identifier.doi10.2174/1570159X13666150612230045
melbourne.affiliation.departmentFlorey Department of Neuroscience and Mental Health
melbourne.affiliation.departmentMelbourne Veterinary School
melbourne.source.titleCurrent Neuropharmacology
melbourne.source.volume13
melbourne.source.issue6
melbourne.source.pages739-749
dc.rights.licenseCC BY-NC
melbourne.elementsid1023592
melbourne.contributor.authorDean, Brian
melbourne.contributor.authorGibbons, Andrew
melbourne.contributor.authorScarr, Elizabeth
melbourne.contributor.authorJEON, WON
dc.identifier.eissn1875-6190
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record